Other studies, such as the TransATAC study, used PAM50 gene expression profiling in order to predict the risk of late recurrence and to explore which hormone-receptor-positive breast cancer would benefit most from extended endocrine therapy beyond the standard 5 years [62]. This evidence concerns the gene NR4A1 and breast cancer.